With VAXCHORA, help protect your clients where they may want to go

Resources for Healthcare Professionals

VAXCHORA video modules

Hover and click on the 3 subject areas below to learn more about VAXCHORA.



Travel-related resources

Explore helpful resources for you and your clients’ travel health needs. Use these links to connect with the resources below.

CDC logo

Centers for Disease Control and Prevention (CDC) Public Health Department Directory

The CDC provides directories for public health departments across the United States. Use this directory to search information regarding public health policies and officials specific to your state or territory.

Navigate to specific health department directories.>
WHO logo

World Health Organization (WHO)

Let your clients know that they can visit the WHO website to learn about cholera.

Visit the cholera webpage.>
PassportHealth logo

Passport Health

Search within the Passport Health website to find travel clinics near you and your clients.

Search for clinics within the United States.>
safegard logo

SafeGard

Let your clients know that they can utilize SafeGard to receive travel health recommendations and information on partnering pharmacies.

Visit the SafeGard homepage.>
e7icon logo

e7 Health

Let your clients know that they can utilize e7 Health for additional travel medicine services.

Visit the Travel Medicine and Vaccines homepage.>




VAXCHORA is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1 in persons 2 through 64 years of age traveling to cholera-affected areas.

Limitations of Use: The effectiveness of VAXCHORA has not been established in persons living in cholera-affected areas. The effectiveness of VAXCHORA has not been established in persons who have pre-existing immunity due to previous exposure to V. cholerae or receipt of a cholera vaccine. VAXCHORA has not been shown to protect against disease caused by V. cholerae serogroup O139 or other non-O1 serogroups.

VAXCHORA is contraindicated in persons who have a history of severe allergic reaction (e.g., anaphylaxis) to any ingredient of VAXCHORA or to a previous dose of any cholera vaccine.

Altered Immunocompetence: The safety and effectiveness of VAXCHORA have not been established in immunocompromised persons and the immunologic response to VAXCHORA may be diminished in immunocompromised individuals.

Shedding and Transmission: Because VAXCHORA may be shed in the stool of recipients for at least 7 days and the vaccine strain can potentially be transmitted to non-vaccinated close contacts (e.g., household contacts), use caution when considering whether to administer VAXCHORA to individuals with immunocompromised close contacts.

Adverse Reactions: In adults 18-45 years old, the most common adverse reactions (incidence > 3%) were tiredness (31%), headache (29%), abdominal pain (19%), nausea/vomiting (18%), lack of appetite (17%) and diarrhea (4%).

The most common adverse reactions for children and adolescents (incidence ≥10%) were:

  • Cohort 1 – age 12-<18 years: headache (45%), tiredness (41%), abdominal pain (38%), lack of appetite (29%) and nausea (22%)
  • Cohort 2 – age 6-<12: tiredness (35%), abdominal pain (27%), headache (26%), lack of appetite (15%) and nausea (14%)
  • Cohort 3 – age 2-<6: tiredness (31%), lack of appetite (19%), and abdominal pain (17%)

Antibiotics: Avoid concomitant administration of VAXCHORA with oral systemic antibiotics since these agents may be active against the vaccine strain. Do not administer VAXCHORA to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination.

Antimalarial Prophylaxis: Immune responses to VAXCHORA may be diminished when administered concomitantly with chloroquine. Administer VAXCHORA at least 10 days before beginning chloroquine.

Immunosuppressive Treatments: Immunosuppressive therapies may reduce the immune response to VAXCHORA.

VAX FULL HCP ISI 01/2021

Please see full Prescribing Information.

Do not use in persons who have a history of severe allergic reaction (e.g., anaphylaxis) to any ingredient of VAXCHORA or to a previous dose of any cholera vaccine.

More

EMERGENT®, VAXCHORA®, VIVOTIF® and all Emergent BioSolutions Inc. brands, products, services and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. All other brands, products, services and feature names or trademarks are the property of their respective owners.

© 2022 Emergent BioSolutions Inc. All rights reserved.

PP-VAX-US-00033 I August 2022

This site is intended for US healthcare professionals only.

This site is intended for US healthcare professionals only.

I am a US HCP I am a patient
Х

You are now leaving vaxchora.com

Vaxchora: Oral Cholera Vaccine Continue
MANAGE PRIVACY

We use cookies on this site (and other similar technologies) to enhance your user experience.

You can manage your Privacy settings on our sites at any time

Thank you for accepting cookies.

You can now hide this message or select MANAGE PRIVACY to edit your privacy permissions at any time.

We use data collected by cookies and JavaScript libraries to improve your browsing experience, analyze site traffic, deliver personalized advertisements, and increase the overall performance of our sites.

You can manage your permissions for how we may use the data we collect using the settings below. These settings describe the current permissions we have enabled for you as a user of one of our sites. To change any permission, select YES to provide permission or NO to revoke or disallow permissions for any of the Categories or Purposes listed below.

For more information about how we handle personal information that you provide to us, you may access this site’s Privacy Policy at any time.

You can also SUPPRESS or DELETE any information you've shared with us at any time.